The 3243 A>G mutation in mitochondrial DNA is the most common cause of monogenic diabetes mellitus in Japan. A 45-year-old woman with mitochondrial diabetes and significant insulin resistance presented with hypoadiponectinemia despite a normal amount of visceral fat. Three months of treatment with pioglitazone (PIO) improved her blood glucose profile and response to the 75-g oral glucose tolerance test. These changes were accompanied by the amelioration of her insulin resistance and the impairment of early-phase insulin secretion. Her serum adiponectin levels increased to the normal range. In this case of mitochondrial diabetes, PIO was effective for glycemic control.
Introduction
Mitochondrial disease is a set of multiple systemic disorders caused by mitochondrial dysfunction in the central nervous system, skeletal muscle, heart and various organs that require energy supplied by the mitochondria. An A>G mutation at position 3243 in mitochondrial DNA (mtDNA) is associated with a subtype of diabetes mellitus with auditory disturbance, muscle atrophy and a short stature. This mutation is the most common cause of monogenic diabetes in Japan, and the patients with this mutation represent approximately 1% of Japanese diabetic patients (1) . A reduced level of insulin secretion has been considered to be a major feature of mitochondrial diabetes (2) (3) (4) (5) . The 3243 A>G mutation in mtDNA reduces the level of ATP generation because of the disruption of the electron transport system (ETS), and the altered ATP to ADP ratio may result in impaired insulin secretion, which can lead to beta-cell apoptosis (6) (7) (8) . A decreased insulin sensitivity is also observed in mitochondrial diabetes (9, 10) . The generation of reactive oxygen species (ROS) in mitochondria due to the disruption of oxidative phosphorylation may cause skeletal muscle atrophy (9-11) and adipose tissue dysfunction, such as the dysregulation of adipocytokines (12, 13), which might lead to an impaired glucose uptake (13, 14). Peroxisome proliferator-activated receptor-gamma (PPAR-gamma) agonists (thiazolidinediones) are insulin sensitizers that reportedly suppress ROS generation in animal models and humans (15, 16). Thiazolidinediones can also raise the plasma level of adiponectin (17, 18), which is an adipose-specific protein with insulin-sensitizing and anti-atherogenic effects.
We herein report a case of mitochondrial diabetes that demonstrated improved glucose intolerance and a low plasma level of adiponectin (hypoadiponectinemia) after treatment with pioglitazone (PIO). Before admission, the patient was treated with miglitol for one month. Table 1 shows the laboratory data at admission. HbA1c improved from 7.8% to 6.2%. The serum adiponectin level was low despite the low BMI and the patient's sex. The serum leptin level was within the normal range. The Matsuda index, calculated using the 75-g OGTT result (21, 22), was 4.0, and the K value from the insulin tolerance test (Kitt) was 2.19%, demonstrating the presence of insulin resistance. Six minutes after injecting 1 mg of glucagon serum C-peptide, the immunoreactivity (CPR) was 4.9 ng/mL, suggesting the preservation of the maximum capacity of insulin secretion. The insulinogenic index (II), calculated using the 75-g OGTT result, was 0.21, which implied an impairment of the first-phase insulin secretion.
The miglitol administration was discontinued because of diarrhea. The patient declined insulin therapy and was administered PIO (7.5 mg/day). After a three-month treatment period, glycemic control, as assessed by HbA1c, was well maintained (6.4%). After injecting glucagon, the serum CPR level remained unchanged. Kitt improved from 2.18% to 2.56%, the Matsuda index improved from 4.04 to 4.38 and II increased from 0.21 to 0.34 ( Fig. 2) . According to the 75-g OGTT, the area under the 0 to 120 min glucose level curve (AUCglu) decreased from 3.3×10 4 mg/dL·min to 2.4× 10 4 mg/dL·min, while the AUCInsulin also decreased from 7.3× 10 4 μU/L·min to 5.1×10 4 μU/L·min. The serum adiponectin level also recovered to within the normal range at 4.5 μg/ mL. The serum levels of IL-6, tumor necrosis factor (TNF)-alpha, thiobarbituric acid reactive substances (TBARS) and leptin were 1.7 pg/mL, 1.0 pg/mL, 4.5 nmol/MDA and 13.3 ng/mL, respectively (Table 2) , and there was no remarkable change after administering PIO (data not shown).
The percent fat and skeletal muscle mass levels were similar to those before administration (Table 3) .
Discussion
To the best of our knowledge, this case report describes the first instance of a patient with mitochondrial diabetes being treated with thiazolidinedione. The PIO treatment was accompanied by improvements of glucose intolerance and hypoadiponectinemia.
PIO is an insulin-sensitizing reagent used to treat type 2 diabetes. To the best of our knowledge, no reports have described the use of PIO in patients with mitochondrial diabetes, most likely because most patients require insulin secretion-promoting therapy or insulin replacement therapy when they visit clinics. The present case demonstrated insulin resistance, as estimated by the Matsuda index and the Insulin Tolerance Test (ITT), and a decreased serum adiponectin level, whereas glucagon-stimulated insulin secretion was preserved. There are two possible reasons why this case showed insulin resistance. One is a low serum adiponectin level that might have been derived from a fat tissue dysfunction (13), while the other is the loss of skeletal muscle mass associated with the mitochondrial mutation (9, 11, 14) . Other factors such as ectopic fat (23) and inflammation (24) are also thought to be associated with insulin resistance, but we could not find any ectopic fat deposition or increases of inflammatory markers such as IL-6 and TNF-alpha in this case. Therefore, further examination would be needed to clarify the association between these factors and insulin resistance.
We expected to observe an insulin-sensitizing effect of the necrosis factor-alpha sTBARS: serum 2-thiobarbituric acid reactive substances thiazolidinedione. In fact, the treatment with PIO for three months improved the glucose tolerance and the insulin sensitivity, as evaluated by the ITT. Biguanide is another potent insulin sensitizer, but we did not use it in this case because of the risk of lactic acidosis (4, 6, 7, 25) . The precise mechanism underlying the insulin-sensitizing effects of PIO in this case remains unclear. However, the hypoadiponectinemia correction may partly explain the improvement in insulin resistance. The amount of adipose tissue was approximately normal in this case, but the serum level of adiponectin was extremely low, suggesting an association of an adipocyte dysfunction with the mitochondrial mutation. Thiazolidinediones are known to bind to the PPAR-responsive element of the adiponectin promoter and to increase the plasma adiponectin level directly (20, 21). Hypoadiponectinemia of less than 4.0 μg/mL is closely associated with metabolic syndrome characterized by insulin resistance in the Japanese (26) . In this case, the pretreatment adiponectin level was very low (2.1 μg/mL) and PIO treatment recovered the adiponectin level to over 4.0 μg/mL, which might have led to the improvement of the insulin resistance. In addition, pretreatment hypoadiponectinemia itself is a predictor of the improvement of glycemic control in PIO treatment (27) . The hypoadiponectinemia in this case might itself have partly contributed to the improvement of the glycemic control.
The PIO also ameliorated the decreased early-phase insulin secretion in this case. It has been reported that thiazolidinediones improve the insulin secretory capacity in patients with type 2 diabetes (28, 29) and preserve the pancreatic beta-cell mass and the pancreatic islet mass (30, 31) . Thiazolidinediones also decrease the overproduction of ROS (15, 16), which might preserve the beta-cell function and protect beta cells from apoptosis in situ; the serum TBARS level did not change in three months. Thiazolidinediones also decrease the serum free fatty acid (FFA) level, which might protect beta cells from lipotoxicity (28, 29) . In this case, the serum FFA level was not measured, therefore this theory is only speculative at this stage.
We herein reported a case with atypical mitochondrial diabetes that presented with insulin resistance but maintained a level of insulin secretory capacity within the normal range. We consider that this atypical feature might have been derived from heteroplasmy of the mtDNA 3243 A>G mutation, and the phenotype of mitochondrial disease is related to the degree of heteroplasmy of each organ (32, 33) .
Mitochondrial diabetes is a progressive disorder in terms of the insulin secretory capacity (34) and the cardiac function (35) . Thiazolidinediones may increase the total plasma volume, which worsens the cardiac function (36, 37) . We should carefully monitor the patient's glycemic control and general condition during PIO treatment.
In conclusion, in this case of mitochondrial diabetes, PIO was found to be effective for achieving glycemic control. 
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